Melanoma-associated antigen 1 (MAGE-A1) (MAGE-A1)

Melanoma-associated antigen 1 (MAGE-A1), historically known as Tumor antigen E or Antigen MZ2-E, is a member of the MAGE family of cancer-testis antigens (CTAs). It was the first human tumor-associated antigen identified to be recognized by autologous cytolytic T lymphocytes (CTLs), marking a milestone in cancer immunology (van der Bruggen et al., Science 1991, PMID: 1840698). Under normal physiological conditions, MAGE-A1 expression is restricted to immune-privileged sites such as the testis and placenta, but it is aberrantly expressed in various malignancies, including melanoma, lung, and breast cancers (UniProt P43355). Biologically, MAGE-A1 functions as a regulator of gene expression and has been implicated in promoting tumor cell survival by inhibiting apoptosis and modulating E3 ubiquitin ligase activity (Gjerstorff et al., 2015, PMID: 25710482). Because of its highly restricted expression in normal tissues and high prevalence in tumors, MAGE-A1 is a primary target for cancer vaccines and T-cell receptor (TCR) engineered T-cell therapies. Therapeutic strategies often involve using epigenetic modifiers like HDAC inhibitors to upregulate MAGE-A1 expression in tumors to enhance the efficacy of targeted immunotherapies.

Other names

MAGE1MAGE-1Antigen MZ2-ETumor antigen ECancer/testis antigen 1.1

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A1 peptides presented by MHC class I molecules (specifically HLA-A1).